SCHEMBL31228007

SCHEMBL31228007

Cn1cc(C2CCN(C(=O)OC(C)(C)C)CC2)nn1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRB P10828 2/20 0.50
KDM4E B2RXH2 2/20 0.50
MAPT P10636 1/20 0.50
EPHX2 P34913 1/20 0.49
CACNA1C Q13936 1/20 0.49
HTT P42858 2/20 0.48
ATM Q13315 1/20 0.48
GPR119 Q8TDV5 6/20 0.47
JAK2 O60674 1/20 0.46
JAK1 P23458 1/20 0.46
TYK2 P29597 1/20 0.46
JAK3 P52333 1/20 0.46
GAA P10253 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
PTPN2 P17706 1/20 0.44
PTPN1 P18031 1/20 0.44
PTPN6 P29350 1/20 0.44
HPGD P15428 2/20 0.44
ALDH1A1 P00352 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22730550 0.82 DDB1 (0.48) THRBKDM4EMAPTHTTATM
SCHEMBL12189221 0.81 HTT (0.60) THRBKDM4EMAPTHTTATM
SCHEMBL8614193 0.81 GRM1 (0.60) THRBMAPTGPR119GAASMN1; SMN2
SCHEMBL22730553 0.80 RORC (0.47) THRBKDM4EMAPTHTTATM
SCHEMBL31582814 0.80 RORC (0.45) THRBKDM4EMAPTHTTATM
SCHEMBL20135095 0.80 GPR119 (0.58) GPR119
SCHEMBL31208153 0.80 HTT (0.53) THRBKDM4EMAPTHTTATM
SCHEMBL22730469 0.79 EPHX1 (0.46) THRBKDM4EMAPTHTTATM
SCHEMBL18865593 0.79 GPR119 (0.50) THRBKDM4EMAPTHTTGPR119
SCHEMBL25731609 0.79 GPR119 (0.50) THRBKDM4EMAPTHTTGPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240400555-A1 Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors INITIAL THERAPEUTICS, INC. (US) 2024-12-05 US disclosed
WO-2024226875-A2 COMPOUNDS, COMPOSITIONS AND METHODS FOR ATTENUATION OF MAMMALIAN TRANSLATION OF C-MYC OR N-MYC PROTEINS OF THE MYC PROTO-ONCOGENE FAMILY OF BHLH TRANSCRIPTION FACTORS INITIAL THERAPEUTICS, INC. (US) 2024-10-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240400555-A1 Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors MYCBP, MYC, MYCBP2 THRB 1724/4885KDM4E 2151/4885MAPT 2934/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.